Stock Events

Stock Events

Tarsus Pharmaceuticals 

$62.5
0
+$0+0% Monday 07:48

Statistics

Day High
75.3
Day Low
62.5
52W High
-
52W Low
-
Volume
50
Avg. Volume
-
Mkt Cap
2.66B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q3 2025
Q4 2025
Next
-0.35
-0.26
-0.18
-0.09
Expected EPS
-0.289222
Actual EPS
N/A

Financials

-14.72%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
902.72MRevenue
-132.84MNet Income

Analyst Ratings

$96.60Average Price Target
The highest estimate is 105.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TARS.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that competes with Tarsus Pharmaceuticals in the development of treatments for eye diseases, including therapies that could directly compete with Tarsus's pipeline products.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is known for its innovations in ophthalmology, making it a direct competitor to Tarsus Pharmaceuticals in the eye care pharmaceutical market.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie, through its acquisition of Allergan, has a strong presence in the ophthalmology sector, competing with Tarsus Pharmaceuticals in developing treatments for eye conditions.
Bausch Health Companies
BHC
Mkt Cap2.62B
Bausch Health Companies, formerly Valeant Pharmaceuticals, has a significant portfolio of eye health products that compete with Tarsus Pharmaceuticals' offerings.
Alcon
ALC
Mkt Cap36.88B
Alcon specializes in eye care products, including pharmaceuticals and devices, making it a competitor to Tarsus Pharmaceuticals in the ophthalmology space.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its Vision Care division, competes with Tarsus Pharmaceuticals in the eye health market, particularly in treatments and products for eye diseases.
Rogers
ROG
Mkt Cap1.57B
Roche, with its ophthalmology division, competes in the same space as Tarsus Pharmaceuticals, particularly in the development of drugs for eye diseases.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a diversified portfolio that includes treatments for eye diseases, positioning it as a competitor to Tarsus Pharmaceuticals in the ophthalmology drug market.

About

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Show more...
CEO
ISIN
US87650L1035

Listings

XNAS
US
TARS
BOATS
BOATS
TARS.BOATS

0 Comments

Share your thoughts

FAQ

What is Tarsus Pharmaceuticals stock price today?▼
The current price of TARS.BOATS is $62.5 USD — it has increased by +0% in the past 24 hours. Watch Tarsus Pharmaceuticals stock price performance more closely on the chart.
What is Tarsus Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Tarsus Pharmaceuticals stocks are traded under the ticker TARS.BOATS.
What is Tarsus Pharmaceuticals market cap?▼
Today Tarsus Pharmaceuticals has the market capitalization of 2.66B
When is the next Tarsus Pharmaceuticals earnings date?▼
Tarsus Pharmaceuticals is going to release the next earnings report on May 12, 2026.
What were Tarsus Pharmaceuticals earnings last quarter?▼
TARS.BOATS earnings for the last quarter are -0.2 USD per share, whereas the estimation was -0.09 USD resulting in a -115.11% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Tarsus Pharmaceuticals revenue for the last year?▼
Tarsus Pharmaceuticals revenue for the last year amounts to 902.72M USD.
What is Tarsus Pharmaceuticals net income for the last year?▼
TARS.BOATS net income for the last year is -132.84M USD.
When did Tarsus Pharmaceuticals complete a stock split?▼
Tarsus Pharmaceuticals has not had any recent stock splits.